Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 83

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 83
---
 offer one or more series of preferred stock, any or all of which could
rank equally with or have preferences over our common stock as to dividend payments, voting rights, rights upon liquidation or other
types of rights. Our board of directors has the authority, without further action by the stockholders, to issue shares of preferred stock
in one or more series and to fix the rights, preferences and the number of shares constituting any series or the designation of such
series. In the case our board of directors decides to issue any preferred stock, we would have no obligation to consider the specific
interests of the holders of common stock in creating any such series of preferred stock or engaging in any such offering or transaction.
Our creation of any series of preferred stock or our engaging in any such offering or transaction could have a material adverse effect
on holders of our common stock.

Trading
of our common stock may be limited, making it difficult for our stockholders to sell their shares, and future sales of common stock could
reduce our stock price.

Our
common stock currently trades on Nasdaq under the ticker “SHPH.” The liquidity of our common stock may be limited, including
in terms of the number of shares that can be bought and sold at a given price and reduction in security analysts’ and the media’s
coverage of us, if any. These factors may result in different prices for our common stock than might otherwise be obtained in a more
liquid market and could also result in a larger spread between the bid and asked prices for our common stock. In addition, in the absence
of a large market capitalization, our common stock is less liquid than the stock of companies with broader public ownership, and, as
a result, the trading prices of our common stock may be more volatile. In the absence of an active public trading market, an investor
may be unable to liquidate his/her investment in our common stock. Trading of a relatively small volume of our common stock may have
a greater impact on the trading price of our stock. We cannot predict the prices at which our common stock will trade in the future,
if at all.

FINRA
sales practice requirements may limit a stockholder’s ability to buy and sell our securities.

Effective
June 30, 2020, the SEC implemented Regulation Best Interest requiring that “A broker, dealer, or a natural person who is an associated
person of a broker or dealer, when making a recommendation of any securities transaction or investment strategy involving securities
(in